Private Companies
New Study Shows Psychedelics Associated With Decrease Use of Other Substances
A new study shows that psychedelic use was associated with a decreased use of other drugs and substances.
The post New Study Shows Psychedelics Associated…
A new study shows that psychedelic use was associated with a decreased use of other drugs and substances.
The research paper, entitled Changed Substance Use After Psychedelic Experiences Among Individuals in Canada showed that participants reported substantially decreasing or completely stopping alcohol, cocaine, or antidepressant usage.
Published in the International Journal of Mental Health and Addiction and sponsored by Psygen Labs and MAPS PBC (Multidisciplinary Association of Psychedelic Studies Public Benefit Corp), the study looked at data from a cross-sectional online survey of over 1600 adults. The participants self-reported a detailed questionnaire about their use of psychedelics and subsequent use of other substances.
Participants reported substantial changes, with 43.8% decreasing or ceasing alcohol use, 42.5% ceasing or decreasing antidepressant use, and 42.4% decreasing or ceasing cocaine use.
Participants reported that the reduction in their substance usage was due to changes in feelings after psychedelics, namely feeling less anxious and less depressed, as well as more connected to others, nature, and themselves.
While this is self-reported and without clinical controls — and needs to be replicated in a stricter setting — the sample size and consistency with results from similar studies make this another compelling data point in psychedelic medicine’s potential.
The post New Study Shows Psychedelics Associated With Decrease Use of Other Substances appeared first on Microdose.
psychedelics psychedelic psygen research-
Law & Regulation1 week ago
Compass Pathways, Journey Clinical to develop psilocybin treatment delivery model
-
Psychedelics1 week ago
MindBio Therapeutics Announces Landmark Women’s Health CNS Drug Trials
-
Psychedelics1 week ago
Reunion Neuroscience Inc. Announces $103 Million Series A Financing Co-Led by MPM BioImpact and Novo Holdings
-
Psychedelics1 week ago
Compass Pathways establishes research collaboration with Mindful Health Solutions to inform the development of a scalable and cost-effective delivery model for investigational COMP360 psilocybin treatment
-
Law & Regulation1 week ago
Compass Pathways, Journey Clinical to develop psilocybin treatment delivery model
-
Ketamine1 week ago
What marijuana reclassification could mean for health treatments
-
Psychedelics1 week ago
MindBio Therapeutics Announces Landmark Women’s Health CNS Drug Trials
-
Psychedelics1 week ago
Compass Pathways establishes research collaboration with Mindful Health Solutions to inform the development of a scalable and cost-effective delivery model for investigational COMP360 psilocybin treatment